A Phase 3, Randomized, Efficacy And Safety Study Of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, And Placebo Plus Leuprolide In Men With High-risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Enzalutamide (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMBARK
- Sponsors Medivation; Pfizer
- 31 Jul 2017 Planned End Date changed from 1 Dec 2020 to 9 Nov 2024.
- 31 Jul 2017 Planned primary completion date changed from 1 Dec 2020 to 27 Aug 2021.
- 10 Jun 2017 Biomarkers information updated